Biliary lipid secretion in man

Lanzini, Alberto; Northfield, T.C.

doi:10.1111/j.1365-2362.1991.tb01369.x

Cited by 17 publications

(7 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34,35 It is now acknowledged that one of the most important determinants of biliary lipid secretion is the structure of the secreted bile acid. 42,43 In the present study, TUDCA induced a low secretion of biliary lipids that was comparable with that reported after FIG. 3.…”

Section: Biliary Lipid Secretion and Bile Flowsupporting

confidence: 78%

“…27 This study was specifically designed to investigate the efhepatocyte plasma membrane by bile acids, in relation to their detergent properties; (2) regulation of the intracellular fect of THDCA vs. TUDCA on biliary lipids, and no information could be extrapolated on the metabolism of both bile assembly and transport of biliary lipids to the bile canaliculus by bile acids; or (3) both of these. 42,43 acids, first because of the antibiotic treatment the subjects underwent, and second for the lack of evaluation of fecal During THDCA infusion, we observed no increase in biliary alkaline phosphatase concentration, which is usually found loss, biliary excretion of bile acid glucuronides, and urinary elimination of bile acids and their conjugates. when hydrophobic bile acids are administered 34 ; this might indicate that the interaction of THDCA with the canalicular In patient B.V., treatment with phenytoin, which is a cytochrome P450 inducer 58 as phenobarbital, 59 might have been plasma membrane is weak and similar to that of TUDCA.…”

Section: Aid Hepa 0049mentioning

confidence: 58%

See 1 more Smart Citation

Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans

et al. 1997

View full text Add to dashboard Cite

both bile acids, biliary cholesterol is transported in nonThis study aimed to determine the effect in humans micellar aggregates. Finally, in the conditions of our of taurohyodeoxycholic acid, a 6a-hydroxylated bile acid study, taurohyodeoxycholic acid was not hepatotoxic. with hydrophilic properties, on bile lipid secretion. Four (HEPATOLOGY 1997;25:1306-1314.) cholecystectomized patients who had gallstones and an interrupted enterohepatic circulation were intraduodenally infused with taurohyodeoxycholic and tauroursoHyodeoxycholic acid (HDCA) is a 6a-dihydroxylated natudeoxycholic acids on separate occasions at a dose of 0.8 ral bile acid (3a-, 6a-dihydroxy-5b-cholan-24-oic acid) found to 1 g/h for 3 hours. In hourly bile samples collected for in pig and rat bile. [1][2][3] In humans, 6a-hydroxylated bile acids 8 hours after the beginning of the infusion, biliary bile are present in trace amounts in the urine in physiological acid composition (by high-performance liquid chroma-conditions, 4 and in increased amounts in cholestatic liver distography), biliary lipid concentrations (by standard eases, 5,6 suggesting that in humans the 6a-hydroxylation is methods), and distribution of biliary carriers (by gel a metabolic pathway that, repressed in normal conditions, chromatography) were evaluated. Blood liver function can be derepressed in pathological situations. tests were performed before and after the infusions.HDCA, because of the presence of a hydroxyl group in the Taurohyodeoxycholic and tauroursodeoxycholic acids 6a position of the steroid ring, is a highly hydrophilic bile became the predominant biliary bile acids in all patients acid. 7,8 It is known that the enrichment of the endogenous except for one infused with taurohyodeoxycholic acid. bile acid pool with hydrophilic bile acids such as ursodeoxyTaurohyodeoxycholic acid stimulated significantly cholic acid (UDCA) has two main clinical effects: (1) it induces greater (P õ .05) cholesterol and phospholipid secretion the dissolution of cholesterol gallstones 9,10 by a reduction of per unit of secreted bile acid (0.098 and 0.451 mmol/mmol, bile cholesterol saturation 11,12 because of a decrease in biliary respectively) compared with tauroursodeoxycholic acid cholesterol secretion, 13,14 and (2) it improves results of liver (0.061 mmol/mmol for cholesterol and 0.275 mmol/mmol function tests in patients with liver disease, 15-17 possibly refor phospholipids). The secretory ratio between phos-lated to a decreased detergency and cell-damaging potency pholipid and cholesterol was significantly higher after of the physiological bile acid pool. 18,19 infusion of taurohyodeoxycholic acid (3.88 mmol/mmol) HDCA has been reported to prevent gallstone formation in compared with taroursodeoxycholic acid (3.09 mmol/ hamsters fed a fat-free, glucose-enriched diet [20][21][22] and in praimmol) (P õ .05). Biliary enrichment with taurohyodeoxy-rie dogs fed a cholesterol-containing diet. [23][24][25] This effect was cholic acid was positively related with percent concen-n...

show abstract

Section: Biliary Lipid Secretion and Bile Flowsupporting

confidence: 78%

Section: Aid Hepa 0049mentioning

confidence: 58%

Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Intracanalicular bile salt micelle formation cannot be the only factor regulating biliary lipid secretion. This would not be in agreement with a number of observations: (1) Presence of cholesterol-phospholipid vesicles in native bile samples [54-561; (2) the isolated hypo-or hypersecretion of phospholipids [46] and of cholesterol [57,58] under certain experimental conditions; (3) the highly species-specific lipid-to-bile salt ratio [53].…”

Section: Coupling Of Pc and Cholesterol Secretioncontrasting

confidence: 38%

“…The relative hydrophobicity of a bile salt is reflected in its critical micellar concentration (CMC). The observed quantitative differences between the amount of lipid secreted per amount of bile salt in different species could be explained by differences in bile salt species present in the bile salt pool [53]. Intracanalicular bile salt micelle formation cannot be the only factor regulating biliary lipid secretion.…”

Section: Coupling Of Pc and Cholesterol Secretionmentioning

confidence: 99%

See 1 more Smart Citation

MDR2 P-glycoprotein-mediated lipid secretion and its relevance to biliary drug transport

Frijters

Groen

Elferink

1997

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects

Loria¹,

Bertolotti²,

Cassinadri³

et al. 1994

Hepatology

View full text Add to dashboard Cite

To test whether de novo synthesis of cholesterol is a limiting factor for bile acid synthesis, we studied the acute effect of simvastatin, an inhibitor of HMG-coenzyme A reductase (the limiting step of cholesterol synthesis) on bile acid synthesis and biliary lipid secretion in subjects with interrupted enterohepatic circulation. In these conditions bile acid synthesis is derepressed and is assumed to equal biliary bile acid secretion. Five cholecystectomized patients fitted with T-tubes were studied. All subjects were administered simvastatin (80 mg as a single dose) 5 days after surgery. Bile was collected in 3-hr intervals for 15 hr before and 30 hr after the administration of the drug. During the experiment we kept the enterohepatic circulation of bile acid interrupted by inflating an occludable balloon inserted, during cholecystectomy, in the common bile duct. Simvastatin induced significant decreases of plasma total and low density lipoprotein cholesterol concentrations, from 163 +/- 29 mg/dl and 97 +/- 24 mg/dl of the pretreatment value to 144 +/- 30 mg/dl and 82 +/- 22 mg/dl 18 hr after simvastatin administration, respectively. Bile flow tended to increase after simvastatin, and the mean values from the third to the 15th hour after simvastatin administration (22.1 +/- 1.9 ml/hr) were significantly greater than the mean values of the pretreatment period (19.9 +/- 2.8 ml/hr). Concomitantly biliary bile acid, cholesterol and phospholipid concentrations fell from basal values of 15.9 +/- 5.1, 2.3 +/- 0.3 and 5.5 +/- 0.3 mmol/L to mean values, after treatment, of 9.0 +/- 3.5, 1.9 +/- 0.5 and 3.0 +/- 0.9 mmol/L, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Biliary lipid secretion in man

Cited by 17 publications

References 159 publications

Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans

Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans

MDR2 P-glycoprotein-mediated lipid secretion and its relevance to biliary drug transport

Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects

Contact Info

Product

Resources

About